KROS Keros Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: KROS

Price (delayed)

$10.77

Market cap

$213.16M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.53

Enterprise value

-$53.48M

?
Relative Growth: Rel. Growth: 0
Relative Strength: Rel. Strength: 11
Relative Valuation: Rel. Valuation: 12
Relative Profitability: Rel. Profitability: 22

Keros is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematologic and musculoskeletal disorders with high unmet medical need. Keros ...

Highlights
The quick ratio has soared by 54% from the previous quarter and by 17% YoY
The debt has contracted by 11% YoY and by 3.4% from the previous quarter
The company's net income has shrunk by 198% QoQ
The revenue has dropped by 86% since the previous quarter and by 85% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://www.kerostx.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of KROS

KROS stock price

How has the Keros Therapeutics stock price performed over time
Intraday
2.57%
1 week
-5.44%
1 month
-8.03%
1 year
-27.33%
YTD
-47.1%
QTD
-2.45%

Financial performance

How have Keros Therapeutics's revenue and profit performed over time
Revenue
$33.18M
Gross profit
$33.18M
Operating income
-$110.35M
Net income
-$85.15M
Gross margin
100%
Net margin
-256.6%
The company's net income has shrunk by 198% QoQ
The revenue has dropped by 86% since the previous quarter and by 85% year-on-year
The gross profit has plunged by 86% from the previous quarter and by 85% YoY

Price vs fundamentals

How does KROS's price correlate with its fundamentals

Growth

What is Keros Therapeutics's growth rate over time

Valuation

What is Keros Therapeutics stock price valuation
P/E
N/A
P/B
0.74
P/S
6.37
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-1.61
The price to book (P/B) is 78% lower than the 5-year quarterly average of 3.3 and 35% lower than the last 4 quarters average of 1.1
KROS's equity has dropped by 61% year-on-year and by 6% since the previous quarter
KROS's P/S is 100% below its 5-year quarterly average of 9709.2 but 73% above its last 4 quarters average of 3.6
The revenue has dropped by 86% since the previous quarter and by 85% year-on-year

Efficiency

How efficient is Keros Therapeutics business performance

Dividends

What is KROS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for KROS.

Financial health

How did Keros Therapeutics financials performed over time
KROS's total assets has shrunk by 60% YoY and by 8% QoQ
The quick ratio has soared by 54% from the previous quarter and by 17% YoY
The debt is 94% less than the equity
KROS's debt to equity has soared by 100% year-on-year
KROS's equity has dropped by 61% year-on-year and by 6% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.